Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Update

Vaccinex, Inc. (NASDAQ:VCNX) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 8,800 shares, a decrease of 40.5% from the February 29th total of 14,800 shares. Based on an average trading volume of 11,100 shares, the short-interest ratio is presently 0.8 days. Currently, 1.5% of the shares of the stock are short sold.

Vaccinex Price Performance

NASDAQ VCNX opened at $7.41 on Friday. Vaccinex has a twelve month low of $7.16 and a twelve month high of $100.80. The business’s fifty day moving average is $8.64 and its 200 day moving average is $12.44.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Vaccinex by 16.7% during the first quarter. Vanguard Group Inc. now owns 727,265 shares of the company’s stock worth $960,000 after purchasing an additional 104,083 shares during the period. Worth Venture Partners LLC lifted its holdings in Vaccinex by 417.0% during the 3rd quarter. Worth Venture Partners LLC now owns 717,559 shares of the company’s stock worth $811,000 after buying an additional 578,764 shares during the period. Armistice Capital LLC acquired a new position in Vaccinex during the 3rd quarter worth about $768,000. Millennium Management LLC grew its position in shares of Vaccinex by 391.2% in the 2nd quarter. Millennium Management LLC now owns 151,666 shares of the company’s stock valued at $164,000 after buying an additional 120,787 shares during the last quarter. Finally, Citadel Advisors LLC increased its stake in shares of Vaccinex by 92.1% in the third quarter. Citadel Advisors LLC now owns 100,268 shares of the company’s stock valued at $50,000 after buying an additional 48,064 shares during the period. Institutional investors and hedge funds own 50.11% of the company’s stock.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.